文献速递免疫规划

基于LASV GPC假型病毒的报告系统可在非BSL-4条件下评估小鼠疫苗

An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions.
PubMed 文献 · Vaccine · 2017-08-07

研究构建含萤火虫荧光素酶报告基因的拉沙病毒糖蛋白前体假型HIV,建立非BSL-4条件下BALB/c小鼠单轮感染生物发光成像模型,以荧光素酶强度为终点评估疫苗效力。DNA疫苗pSV1.0-LASVGPC和假病毒颗粒疫苗LASVpp分别经肌内电穿孔和腹腔途径接种小鼠,单独LASVpp及DNA初免+LASVpp加强组均抵抗100 AID50假病毒攻击,体内效力与抗LASV中和活性及血清MCP-1水平相关。

要点

  • 构建LASV GPC假型HIV报告病毒,电镜下结构与天然病毒颗粒相似。
  • LASVpp单独及DNA初免+LASVpp加强组均抵抗100 AID50假病毒攻击。
  • 保护效力与感染前血清抗LASV中和活性及MCP-1水平相关。

核心结论

  • 生物发光假病毒感染模型可作为非BSL-4条件下初步评估LASV候选疫苗免疫原性和效力的工具。
  • 假病毒颗粒疫苗的结果为LASV疫苗设计提供了有用信息。

研究设计与样本

  • 构建含萤火虫荧光素酶报告基因的LASV GPC假型HIV,建立非BSL-4条件下BALB/c小鼠单轮感染生物发光成像模型。
  • 以荧光素酶生物发光强度为终点评估疫苗效力。
  • 构建DNA疫苗pSV1.0-LASVGPC和展示LASV Josiah株构象GPC蛋白的假病毒颗粒疫苗LASVpp,分别经肌内电穿孔和腹腔途径接种BALB/c小鼠。

主要发现

  • 电镜分析显示LASV GPC假型病毒在结构上与天然病毒颗粒相似。
  • LASVpp单独及DNA初免+LASVpp加强组接种小鼠均抵抗100 AID50 LASV假病毒攻击。
  • 体内效力与感染前血清抗LASV中和活性及MCP-1细胞因子水平相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lassa virus (LASV) causes a severe hemorrhagic fever endemic throughout western Africa. Because of the ability to cause lethal disease in humans, limited treatment options, and potential as a bioweapon, the need for vaccines to prevent LASV epidemic is urgent. However, LASV vaccine development has been hindered by the lack of appropriate small animal models for efficacy evaluation independent of biosafety level four (BSL-4) facilities. Here we generated an LASV-glycoprotein precursor (GPC)-pseudotyped Human immunodeficiency virus containing firefly luciferase (Fluc) reporter gene as surrogate to develop a bioluminescent-imaging-based BALB/c mouse model for one-round infection under non-BSL-4 conditions, in which the bioluminescent intensity of Fluc was utilized as endpoint when evaluating vaccine efficacy. Electron microscopy analysis demonstrated that LASV GPC pseudotyped virus appeared structurally similar to native virion. Meanwhile, we constructed DNA vaccine (pSV1.0-LASVGPC) and pseudoparticle-based vaccine (LASVpp) that displayed conformational GPC protein of LASV strain Josiah to vaccinate BALB/c mice using intramuscular electroporation and by intraperitoneal routes, respectively. Vaccinated mice in LASVpp alone and DNA prime+LASVpp boost schedules were protected against 100 AID50 of LASV pseudovirus challenge, and it was found that in vivo efficiencies correlated with their anti-LASV neutralizing activities and MCP-1 cytokine levels in serum sampled before infection. The bioluminescence pseudovirus infection model can be useful tool for the preliminary evaluation of immunogenicity and efficacy of vaccine candidates against LASV outside of BSL-4 containments, and the results with pseudoparticle-based vaccine provided very helpful information for LASV vaccine design.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li Q, Liu Q, Huang W, et al. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. Vaccine. 2017. PMID: 28797730. doi:10.1016/j.vaccine.2017.07.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。